Kidney Injuries | Medical XPRT
Articles & Whitepapers
-
Advances in siRNA Drug Research
siRNA, with a molecular weight of about 13 kDa, recruits the RNA-induced silencing complex (RISC) to mRNA through base pairing, thereby inhibiting protein translation. The mRNA is targeted for cleavage through the catalysis of the RISC protein Ago2, a member of the Argonaute family. In addition, other Ago proteins (Ago1, Ago3, and Ago4) catalyze endonuclease-mediated degradation of non-specific ...
-
Cytokine Involvement in Inflammatory Immune Disorders
Cytokines, small molecules with potent biological activity, are primarily synthesized by immune and non-immune cells (e.g., vascular endothelial cells, epidermal cells, fibroblasts) in response to ...
News
-
Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes
Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) CKD affects up to 40% of people with T1D A ...
Ovivo’s Women for Water presents: Astrid Kloosterman
New real world study data on reduced risk of adverse kidney outcomes for Xarelto compared to VKA
Juvena Therapeutics Bolsters Leadership Team With Key Industry Veterans in Drug Discovery and Development, Data Science, and Business Development
Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes
Equipment & Solutions
-
Showcase
cfDNA Kit
AlloSeq cfDNA is a minimally invasive blood test that measures the amount of donor-derived cell-free DNA (dd-cfDNA) for transplant surveillance. It is currently only available outside of the United States.